Does the media prefer VCEL or PRAX?

In the previous week, Vericel had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Vericel and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.50 beat Vericel's score of 0.41 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VCEL or CRNX?

In the previous week, Vericel had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 7 mentions for Vericel and 5 mentions for Crinetics Pharmaceuticals. Vericel's average media sentiment score of 0.41 beat Crinetics Pharmaceuticals' score of 0.08 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, VCEL or TGTX?

TG Therapeutics has higher revenue and earnings than Vericel. TG Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.48 $16.52M $0.42 109.24 TG Therapeutics $616.29M 13.40 $447.18M $2.86 18.87

Is VCEL or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Vericel's net margin of 7.35%. TG Therapeutics' return on equity of 88.73% beat Vericel's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% TG Therapeutics 65.95% 88.73% 43.44%

Does the media refer more to VCEL or TGTX?

In the previous week, TG Therapeutics had 4 more articles in the media than Vericel. MarketBeat recorded 11 mentions for TG Therapeutics and 7 mentions for Vericel. Vericel's average media sentiment score of 0.41 beat TG Therapeutics' score of 0.37 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, VCEL or IBRX?

Vericel has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.48 $16.52M $0.42 109.24 ImmunityBio $113.29M 69.24 -$351.40M -$0.85 N/A

Is VCEL or IBRX more profitable?

Vericel has a net margin of 7.35% compared to ImmunityBio's net margin of -606.15%. Vericel's return on equity of 6.41% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets Vericel 7.35% 6.41% 4.61% ImmunityBio -606.15% N/A -59.53%

Does the media prefer VCEL or IBRX?

In the previous week, ImmunityBio had 3 more articles in the media than Vericel. MarketBeat recorded 10 mentions for ImmunityBio and 7 mentions for Vericel. ImmunityBio's average media sentiment score of 1.06 beat Vericel's score of 0.41 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, VCEL or SYRE?

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vericel $276.26M 8.48 $16.52M $0.42 109.24 Spyre Therapeutics $890K 9,617.08 -$155.20M -$2.08 N/A

Does the media prefer VCEL or SYRE?

In the previous week, Vericel had 5 more articles in the media than Spyre Therapeutics. MarketBeat recorded 7 mentions for Vericel and 2 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.47 beat Vericel's score of 0.41 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vericel (VCEL) Competitors

$45.88 -0.76 (-1.63%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$45.85 -0.03 (-0.07%)

As of 07:13 AM Eastern

Compare

VCEL vs. PRAX, CRNX, TGTX, IBRX, and SYRE

Should you buy Vericel stock or one of its competitors? MarketBeat compares Vericel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vericel include Praxis Precision Medicines (PRAX), Crinetics Pharmaceuticals (CRNX), TG Therapeutics (TGTX), ImmunityBio (IBRX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Vericel compare to Praxis Precision Medicines?

Vericel (NASDAQ:VCEL) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Vericel had 5 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 7 mentions for Vericel and 2 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.50 beat Vericel's score of 0.41 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Praxis Precision Medicines	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.8% of Praxis Precision Medicines shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vericel has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.48	$16.52M	$0.42	109.24
Praxis Precision Medicines	$8.55M	992.69	-$303.27M	-$13.37	N/A

Vericel has a net margin of 7.35% compared to Praxis Precision Medicines' net margin of 0.00%. Vericel's return on equity of 6.41% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Vericel has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market.

Vericel currently has a consensus price target of $55.50, indicating a potential upside of 20.97%. Praxis Precision Medicines has a consensus price target of $563.50, indicating a potential upside of 85.10%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Praxis Precision Medicines is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

Summary

Vericel beats Praxis Precision Medicines on 9 of the 17 factors compared between the two stocks.

How does Vericel compare to Crinetics Pharmaceuticals?

Vericel (NASDAQ:VCEL) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Vericel currently has a consensus price target of $55.50, indicating a potential upside of 20.97%. Crinetics Pharmaceuticals has a consensus price target of $78.27, indicating a potential downside of 6.67%. Given Vericel's stronger consensus rating and higher probable upside, equities analysts plainly believe Vericel is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29

Vericel has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.48	$16.52M	$0.42	109.24
Crinetics Pharmaceuticals	$7.70M	1,148.47	-$465.32M	-$5.13	N/A

Vericel has a net margin of 7.35% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Vericel's return on equity of 6.41% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Vericel had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 7 mentions for Vericel and 5 mentions for Crinetics Pharmaceuticals. Vericel's average media sentiment score of 0.41 beat Crinetics Pharmaceuticals' score of 0.08 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market.

Summary

Vericel beats Crinetics Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Vericel compare to TG Therapeutics?

Vericel (NASDAQ:VCEL) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

TG Therapeutics has higher revenue and earnings than Vericel. TG Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.48	$16.52M	$0.42	109.24
TG Therapeutics	$616.29M	13.40	$447.18M	$2.86	18.87

In the previous week, TG Therapeutics had 4 more articles in the media than Vericel. MarketBeat recorded 11 mentions for TG Therapeutics and 7 mentions for Vericel. Vericel's average media sentiment score of 0.41 beat TG Therapeutics' score of 0.37 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.6% of TG Therapeutics shares are owned by institutional investors. 7.6% of Vericel shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vericel currently has a consensus target price of $55.50, indicating a potential upside of 20.97%. TG Therapeutics has a consensus target price of $53.33, indicating a potential downside of 1.16%. Given Vericel's higher possible upside, analysts plainly believe Vericel is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Vericel has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Vericel's net margin of 7.35%. TG Therapeutics' return on equity of 88.73% beat Vericel's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Vericel on 13 of the 16 factors compared between the two stocks.

How does Vericel compare to ImmunityBio?

Vericel (NASDAQ:VCEL) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

8.6% of ImmunityBio shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vericel has a net margin of 7.35% compared to ImmunityBio's net margin of -606.15%. Vericel's return on equity of 6.41% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
ImmunityBio	-606.15%	N/A	-59.53%

Vericel presently has a consensus price target of $55.50, suggesting a potential upside of 20.97%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 89.59%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Vericel has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Vericel has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.48	$16.52M	$0.42	109.24
ImmunityBio	$113.29M	69.24	-$351.40M	-$0.85	N/A

In the previous week, ImmunityBio had 3 more articles in the media than Vericel. MarketBeat recorded 10 mentions for ImmunityBio and 7 mentions for Vericel. ImmunityBio's average media sentiment score of 1.06 beat Vericel's score of 0.41 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vericel and ImmunityBio tied by winning 8 of the 16 factors compared between the two stocks.

How does Vericel compare to Spyre Therapeutics?

Vericel (NASDAQ:VCEL) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Vericel has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	8.48	$16.52M	$0.42	109.24
Spyre Therapeutics	$890K	9,617.08	-$155.20M	-$2.08	N/A

In the previous week, Vericel had 5 more articles in the media than Spyre Therapeutics. MarketBeat recorded 7 mentions for Vericel and 2 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.47 beat Vericel's score of 0.41 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.02, suggesting that its stock price is 202% more volatile than the broader market.

Vericel currently has a consensus price target of $55.50, suggesting a potential upside of 20.97%. Spyre Therapeutics has a consensus price target of $101.42, suggesting a potential upside of 4.20%. Given Vericel's higher possible upside, equities research analysts plainly believe Vericel is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

80.4% of Spyre Therapeutics shares are held by institutional investors. 7.6% of Vericel shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vericel has a net margin of 7.35% compared to Spyre Therapeutics' net margin of 0.00%. Vericel's return on equity of 6.41% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.35%	6.41%	4.61%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Vericel beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Vericel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCEL vs. The Competition

Export

Metric	Vericel	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.38B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	109.24	20.49	27.07	23.95
Price / Sales	8.48	300.33	515.72	90.33
Price / Cash	83.96	60.31	26.68	47.25
Price / Book	6.54	7.92	10.62	6.14
Net Income	$16.52M	$23.81M	$3.60B	$331.74M
7 Day Performance	-0.46%	-1.09%	-1.26%	-1.82%
1 Month Performance	14.41%	2.56%	1.07%	-1.45%
1 Year Performance	29.39%	42.16%	23.63%	16.32%

Vericel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCEL Vericel	3.6753 of 5 stars	$45.88 -1.6%	$55.50 +21.0%	+29.8%	$2.38B	$276.26M	109.24	300	Analyst Upgrade
PRAX Praxis Precision Medicines	3.2148 of 5 stars	$314.56 -3.2%	$563.50 +79.1%	+465.3%	$9.06B	$8.55M	N/A	110
CRNX Crinetics Pharmaceuticals	1.2919 of 5 stars	$83.67 +0.1%	$78.27 -6.5%	+169.6%	$8.81B	$7.70M	N/A	210
TGTX TG Therapeutics	3.0549 of 5 stars	$55.01 -3.7%	$53.33 -3.0%	+42.3%	$8.74B	$616.29M	19.23	290
IBRX ImmunityBio	3.5276 of 5 stars	$7.79 -5.2%	$14.20 +82.3%	+172.4%	$8.61B	$113.29M	N/A	590	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCEL) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vericel (VCEL) Competitors

VCEL vs. PRAX, CRNX, TGTX, IBRX, and SYRE

How does Vericel compare to Praxis Precision Medicines?

Summary

How does Vericel compare to Crinetics Pharmaceuticals?

Summary

How does Vericel compare to TG Therapeutics?

Summary

How does Vericel compare to ImmunityBio?

Summary

How does Vericel compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vericel (VCEL) Competitors

VCEL vs. PRAX, CRNX, TGTX, IBRX, and SYRE

How does Vericel compare to Praxis Precision Medicines?

Does the media prefer VCEL or PRAX?

Do insiders and institutionals believe in VCEL or PRAX?

Which has higher valuation & earnings, VCEL or PRAX?

Is VCEL or PRAX more profitable?

Which has more risk & volatility, VCEL or PRAX?

Do analysts prefer VCEL or PRAX?

Summary

How does Vericel compare to Crinetics Pharmaceuticals?

Do analysts recommend VCEL or CRNX?

Which has stronger earnings and valuation, VCEL or CRNX?

Is VCEL or CRNX more profitable?

Do institutionals & insiders believe in VCEL or CRNX?

Does the media prefer VCEL or CRNX?

Which has more risk and volatility, VCEL or CRNX?

Summary

How does Vericel compare to TG Therapeutics?

Which has stronger earnings and valuation, VCEL or TGTX?

Does the media refer more to VCEL or TGTX?

Do institutionals and insiders believe in VCEL or TGTX?

Do analysts recommend VCEL or TGTX?

Which has more risk & volatility, VCEL or TGTX?

Is VCEL or TGTX more profitable?

Summary

How does Vericel compare to ImmunityBio?

Do institutionals & insiders hold more shares of VCEL or IBRX?

Is VCEL or IBRX more profitable?

Do analysts rate VCEL or IBRX?

Which has more risk & volatility, VCEL or IBRX?

Which has higher earnings & valuation, VCEL or IBRX?

Does the media prefer VCEL or IBRX?

Summary

How does Vericel compare to Spyre Therapeutics?

Which has preferable valuation and earnings, VCEL or SYRE?

Does the media prefer VCEL or SYRE?

Which has more risk & volatility, VCEL or SYRE?

Do analysts recommend VCEL or SYRE?

Do institutionals and insiders have more ownership in VCEL or SYRE?

Is VCEL or SYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCEL vs. The Competition

Vericel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools